Joerg Moeller Takes Helm at Antag Therapeutics
Portfolio - People | Jan 08, 2025 | Broadview Ventures
Dr. Joerg Moeller, a seasoned leader with extensive experience in the pharmaceutical and biotechnology sectors, has been appointed as the new Chief Executive Officer of Antag Therapeutics. This strategic move is part of Antag Therapeutics' growth plans as supported by Broadview Ventures, a private equity firm focused on biochemical ventures. Moeller's appointment is expected to drive the company's growth and innovation in therapeutic solutions. Antag Therapeutics focuses on pioneering new treatments, and Broadview Ventures aims to leverage Moeller's industry expertise to enhance the company's strategic direction.
Sectors
- Pharmaceuticals
- Biotechnology
- Private Equity
Geography
- Global – The biotechnology and pharmaceuticals industries have a global impact, and leadership changes in these sectors can influence international markets.
Industry
- Pharmaceuticals – Antag Therapeutics operates within the pharmaceuticals industry, focusing on creating new therapeutic solutions.
- Biotechnology – The appointment of Dr. Joerg Moeller aligns with Antag Therapeutics' involvement in the biotechnology sector, aiming to develop innovative biotechnological treatments.
- Private Equity – Broadview Ventures is a private equity firm investing in Antag Therapeutics to support its strategic growth and development.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Dr. Joerg Moeller | Chief Executive Officer | People | Industry veteran appointed as CEO of Antag Therapeutics. |
| Antag Therapeutics | Target Company | Company | A pharmaceutical company focusing on therapeutic innovations. |
| Broadview Ventures | Private Equity Firm | Company | A private equity firm supporting Antag Therapeutics' strategic goals. |